Nasivin Vicks Classic (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑1 and alpha‑2 adrenergic receptor agonist. When applied to the nasal mucosa, it triggers vasoconstriction of the small blood vessels, decreasing blood flow and edema. This reduction in swelling clears the nasal passages and alleviates the feeling of a blocked nose.

The appropriate dose and frequency are determined by the prescribing healthcare professional based on the product labeling. Typically, the label advises a limited number of sprays per nostril at set intervals, and the total duration of use should not exceed the recommended maximum, usually three days.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider to weigh potential benefits against any possible risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nasivin Vicks Classic contains oxymetazoline, which offers rapid, localized vasoconstriction and typically provides longer relief per dose compared with phenylephrine‑based sprays. However, all topical decongestants share similar cautions regarding limited‑duration use to avoid rebound congestion.

Store the nasal spray at room temperature, preferably below 25 °C. Keep it in the original packaging, protect it from excessive moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

The spray is applied directly into each nostril while the head is upright. The user gently inserts the nozzle into the nostril, presses the pump to deliver the recommended number of sprays, and then repeats in the opposite nostril if instructed. Avoid blowing the nose immediately after use.

Serious risks include rebound nasal congestion (rhinitis medicamentosa) if used beyond the recommended period, significant elevation of blood pressure, tachycardia, and rare cases of severe nasal tissue damage. Patients experiencing these symptoms should discontinue use and seek medical attention promptly.

Individuals with known hypersensitivity to oxymetazoline or any formulation component should avoid the product. It is also contraindicated in patients taking monoamine oxidase inhibitors, those with severe uncontrolled hypertension, and anyone advised by a healthcare professional to refrain from topical nasal decongestants.